MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the European Medicines Agency (“EMEA”) has determined that the Marketing Authorization Application (“MAA”) for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid. Validation of the MAA indicates that ChemGenex’s application, submitted on 29 October 2009, is complete and that the review process has begun. The filing is based on data from pivotal Study 202 where omacetaxine demonstrated clinical benefit for the treatment of T315I positive CML patients.
